Recently, the Third Conference on High-Quality Development of Traditional Chinese Medicine, along with the Seminar on Strategic Research for High-Quality Development of Traditional Chinese Medicine in the New Era, was held in Zhejiang, organized by the National Key Laboratory of Modern Chinese Medicine Development and Tianjin University of Traditional Chinese Medicine.
Attending the academic activities were prominent experts and scholars including Yu Yanhong, Director of the National Administration of Traditional Chinese Medicine, Zhao Junning, Deputy Director of the National Medical Products Administration, academicians such as Chen Kaixian from the Chinese Academy of Sciences, and academicians Zhang Boli, Li Lanjuan, Chen Xiangmei, Li Zhaoshen, Liu Liang, Zhu Zhaoyun, and Tian Jinzhou.
During the event, 50 studies were released under the title "2024 International High-Impact Research on Traditional Chinese Medicine and Traditional Medicine," evaluating aspects such as journal impact, article impact, author impact, public impact, and research impact. These studies were selected from original research in the field of traditional medicine published in 2022, screened by the Evidence-Based Medicine Center of Tianjin University of Traditional Chinese Medicine, forming a nomination pool for high-impact research in international traditional Chinese and traditional medicine fields in 2022.
The selection process also included contributions from the ten major academic advancements in traditional Chinese medicine in 2022 and relevant news on high-level research in traditional Chinese medicine. The final selection was made through open online voting, evaluation by one hundred peer experts, and consensus review by leading figures in the field, recommended by the First Traditional Chinese Medicine Journal International Impact Enhancement Platform.
One of the highlighted studies was a multicenter, randomized, double-blind, parallel-controlled trial on the efficacy of Huangkui Capsules in treating proteinuria in type 2 diabetic kidney disease (DKD). The study confirmed that Huangkui Capsules are equally effective as frontline Western medicine Irbesartan, with additional advantages. Moreover, the combination therapy of the two showed even more significant efficacy, providing DKD patients with more and better treatment options.
